Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Haemonetics (HAE – Research Report), Mesoblast (MESO – Research Report) and HealthStream (HSTM – Research Report).
Haemonetics (HAE)
Barrington analyst Michael Petusky maintained a Buy rating on Haemonetics today and set a price target of $114.00. The company’s shares closed last Thursday at $89.45.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of
Haemonetics has an analyst consensus of Strong Buy, with a price target consensus of $114.67.
See today’s best-performing stocks on TipRanks >>
Mesoblast (MESO)
William Blair analyst Sami Corwin maintained a Hold rating on Mesoblast today. The company’s shares closed last Thursday at $1.26, close to its 52-week low of $1.16.
According to TipRanks.com, Corwin is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Mesoblast with a $7.63 average price target.
HealthStream (HSTM)
Barrington analyst Vincent Colicchio assigned a Hold rating to HealthStream today. The company’s shares closed last Thursday at $21.47, close to its 52-week low of $20.47.
According to TipRanks.com, Colicchio is a 5-star analyst with an average return of
HealthStream has an analyst consensus of Moderate Buy, with a price target consensus of $22.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HAE:
- Haemonetics announces European expansion for Vascade MVP
- Haemonetics price target raised to $114 from $111 at Barrington
- Haemonetics raises FY24 adjusted EPS view to $3.60-$3.90 from $3.45-$3.75
- Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- Haemonetics reports Q1 adjusted EPS $1.05, consensus 73c
